IN2014KN02740A - - Google Patents

Info

Publication number
IN2014KN02740A
IN2014KN02740A IN2740KON2014A IN2014KN02740A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A IN 2740KON2014 A IN2740KON2014 A IN 2740KON2014A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A
Authority
IN
India
Prior art keywords
hiv
provides
polypeptidestabilized
polypeptideor
conformation
Prior art date
Application number
Inventor
Andrea Carfi
Antu Dey
Aemro Kassa
Indresh Srivastava
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014KN02740A publication Critical patent/IN2014KN02740A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an isolated polypeptide comprising an HIV gp120 polypeptideor soluble gp140 polypeptidestabilized in a conformation which exposes both CD4-bound and CD4- binding site epitopes. The invention also provides immunogenic compositions and methods of treating and preventing infection with HIV.
IN2740KON2014 2012-06-18 2013-06-17 IN2014KN02740A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
IN2014KN02740A true IN2014KN02740A (en) 2015-05-08

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2740KON2014 IN2014KN02740A (en) 2012-06-18 2013-06-17

Country Status (14)

Country Link
US (1) US20150183835A1 (en)
EP (1) EP2861249A1 (en)
JP (1) JP2015521592A (en)
KR (1) KR20150023735A (en)
CN (1) CN104619338A (en)
AU (1) AU2013279456A1 (en)
CA (1) CA2876762A1 (en)
IL (1) IL235898A0 (en)
IN (1) IN2014KN02740A (en)
MX (1) MX2014014682A (en)
RU (1) RU2015101081A (en)
SG (1) SG11201407995RA (en)
WO (1) WO2013189901A1 (en)
ZA (1) ZA201408840B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
CN107073100B (en) * 2014-09-23 2021-02-26 勃林格殷格翰动物保健美国公司 FMDV recombinant vaccine and application thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
KR20190091264A (en) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 Multimeric IL-15 Based Molecules
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
CN109851664A (en) * 2017-11-30 2019-06-07 清华大学 A kind of protein based on the reversed epitope design of antibody and its in the application prepared in AIDS virus resisting vaccine
WO2019245993A1 (en) 2018-06-19 2019-12-26 Nantcell, Inc. Hiv treatment compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (en) * 1998-11-27 2003-04-25 Orstom GP120 MUTANTS AND THEIR BIOLOGICAL APPLICATIONS
AU782123B2 (en) * 1999-06-25 2005-07-07 Aaron Diamond Aids Research Center, The Stabilized viral envelope proteins and uses thereof
JP2010536885A (en) * 2007-08-24 2010-12-02 ノバルティス アーゲー HIVENV protein with modifications in the V3 loop
EP2480572B1 (en) * 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use

Also Published As

Publication number Publication date
US20150183835A1 (en) 2015-07-02
AU2013279456A1 (en) 2014-12-18
KR20150023735A (en) 2015-03-05
IL235898A0 (en) 2015-01-29
CA2876762A1 (en) 2013-12-27
SG11201407995RA (en) 2015-01-29
ZA201408840B (en) 2016-08-31
WO2013189901A1 (en) 2013-12-27
MX2014014682A (en) 2015-03-04
RU2015101081A (en) 2016-08-10
EP2861249A1 (en) 2015-04-22
CN104619338A (en) 2015-05-13
JP2015521592A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IN2014KN02740A (en)
CY1124043T1 (en) HUMAN IMMUNODEFICIENCY VIRUS-NEUTRALIZING ANTIBODIES AND METHODS OF USING THEM
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201891186A1 (en) ANTIBODIES, NEUTRALIZING THE VIRUS OF HUMAN IMMUNODEFICIENCY
WO2013085550A3 (en) V1v2 immunogens
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015501156A1 (en) Pharmaceutical compositions
EA201290956A1 (en) VACCINE AGAINST HIV
WO2013016468A3 (en) Compositions and methods for improving potency and breadth or hiv antibodies
MX2015015500A (en) Cenicriviroc compositions and methods of making and using the same.
WO2012047267A3 (en) Polyvalent immunogen
MX349119B (en) Inactivated dengue virus vaccine.
IN2015DN03202A (en)
WO2011106100A3 (en) Method of inducing the production of protective anti-hiv-1 antibodies
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
IN2014CH00395A (en)
EA201790495A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION
UA118542C2 (en) Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
IN2014DN09445A (en)
WO2015086738A3 (en) Hiv vaccine
AU2013235442A8 (en) Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate
MX350718B (en) Equine rhinitis vaccine.
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association